When considering accomplishments recorded in the arena of gene therapy, the “firsts” are impressive.
AU-011 (Aura Biosciences) is a first-in-class drug being investigated as a treatment for choroidal melanoma with promising early results being reported from an ongoing phase Ib/II clinical trial, according to Amy Schefler, MD.
For patients with meibomian gland disfunction (MGD), the LipiFlow thermal pulsation system allows physicians to treat patients in office with confidence and efficiency.
The future of glaucoma will likely not resemble the current state of management of the disease, with numerous advances on the horizon, according to Harry Quigley MD, the A.
This article was reviewed by Bita Esmaeli, MD, FACS
This article was reviewed by Christophe Baudouin, MD, PhD, FARVO